Disease-modifying anti-rheumatic drugs (DMARDs) reduce tissue destruction by suppressing the auto-immune attack on the joints.
Serum acute phase proteins (ACP) are measured monthly to assess the effectiveness of DMARDs such as:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.